Pharmacognosy Area, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Suipacha 531, 2000-Rosario, Argentina.
Molecules. 2013 May 15;18(5):5669-83. doi: 10.3390/molecules18055669.
Eighteen (3R) and (3R,4R)-N-phenyl-, N-phenylalkyl and N-arylsuccinimides were prepared with high enantioselectivity by biotransformation of maleimides with A. fumigatus. This environmentally friendly, clean and economical procedure was performed by the whole-cell fungal bioconversion methodology. Their corresponding eighteen racemic succinimides were prepared instead by synthetic methods. Both, the racemic and the chiral succinimides were tested simultaneously by the microbroth dilution method of CLSI against a panel of human opportunistic pathogenic fungi of clinical importance. Chiral succinimides showed higher antifungal activity than the corresponding racemic ones and the differences in activity were established by statistical methods. The bottlenecks for developing chiral drugs are how to obtain them through a low-cost procedure and with high enantiomeric excess. Results presented here accomplish both these objectives, opening an avenue for the development of asymmetric succinimides as new antifungal drugs for pharmaceutical use.
18 种(3R)和(3R,4R)-N-苯基、N-苯烷基和 N-芳基琥珀酰亚胺通过曲霉菌属(A. fumigatus)对马来酰亚胺的生物转化高对映选择性地制备。这种环保、清洁和经济的方法通过全细胞真菌生物转化方法进行。它们相应的 18 种外消旋琥珀酰亚胺则通过合成方法制备。通过 CLSI 的微量肉汤稀释法,同时对一组具有临床重要意义的人体机会性致病真菌对这两种外消旋和手性琥珀酰亚胺进行测试。手性琥珀酰亚胺显示出比相应的外消旋体更高的抗真菌活性,活性差异通过统计方法确定。开发手性药物的瓶颈在于如何通过低成本的方法获得高对映体过量的手性药物。本文介绍的结果同时实现了这两个目标,为开发作为医药用途的新型抗真菌药物的不对称琥珀酰亚胺开辟了道路。